DEFA14A ·Filed Apr 3, 2026

RIGL

RIGEL PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001034842-26-000024
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine SEC filing with no actionable financial information. Traders should ignore this filing as it does not contain any material information about the company's operations, financials, or strategic direction. Monitor for the release of the full proxy statement for any material information.

DirectionNeutral
Confidencelow
Horizonimmediate
Final — all horizons settled through T+60d
RIGL ▲ +39.95% at T+60d
NEUTRAL call ✓ call won +39.95% · α vs SPY +26.48% · entry $27.36 → $38.29
Entry anchored
Apr 2, 03:59 PM ET
via exchange tick
T+1d
+5.01%
call +5.01% · α +4.94%
$28.73
settled 6mo ago
T+5d
+9.54%
call +9.54% · α +5.40%
$29.97
settled 6mo ago
T+20d
+7.97%
call +7.97% · α -1.01%
$29.54
settled 5mo ago
T+60d
+39.95%
call +39.95% · α +26.48%
$38.29
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

RIGEL PHARMACEUTICALS INC filed a Definitive Additional Materials (DEFA14A) form, which is supplementary proxy solicitation material related to a shareholder vote. The documents provided are primarily technical SEC filing headers and do not contain substantive information about the vote, such as what is being voted on, the outcome, or management's position. This is a routine administrative filing.

Key Facts

  • The filing is a DEFA14A, which is Definitive Additional Materials for a proxy statement.
  • The documents provided are technical SEC headers and a graphic, not the substantive proxy statement content.
  • The filing is routine and administrative in nature.
  • No information about the vote, candidates, or issues is available in the provided documents.

Financial Impact

No financial impact information available.

Risk Factors

  • The provided documents are incomplete and do not contain the actual proxy statement content.
  • There is a risk of misinterpreting this routine filing as a material event.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001034842-26-000024
Document: 0001034842-26-000024-index-headers.html0001034842-26-000024
Document: 0001034842-26-000024-index.html0001034842-26-000024
Document: 0001034842-26-000024.txt0001034842-26-000024
8 reports for RIGL
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +25.02%May 12, 2026
Filters
Rows
Reports for RIGL — sortable, filterable
TypeNow
Aug 4, 2026
8w ago
8-K
MIXED ★ 6/10
$40.48 $49.42▲ +22.09%▲ +22.69%$46.50 (+14.87%)
Jun 17, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$32.91 $41.67▲ +26.62%▲ +26.09%$46.50 (+41.29%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 3/10
$32.08 $43.76▲ +36.41%▲ +34.52%$46.50 (+44.95%)
May 20, 2026
19w ago
8-K
NEUTRAL ★ 2/10
$29.19 $35.78▲ +22.58%▲ +22.24%$46.50 (+59.30%)
May 12, 2026
20w ago
8-K
BULLISH ★ 7/10
$32.13 $32.08▼ −0.16%▲ +0.46%$46.50 (+44.72%)
May 5, 2026
21w ago
8-K
BEARISH ★ 7/10
$26.67 $30.30▼ −13.61%▼ −10.83%$46.50 (−74.35%)
Apr 21, 2026
23w ago
8-K
BEARISH ★ 7/10
$30.47 $28.30▲ +7.12%▲ +10.29%$46.50 (−52.61%)
Apr 3, 2026
25w ago
DEFA14A
NEUTRAL ★ 2/10
$27.36 $29.54▲ +7.97%▼ −1.01%$46.50 (+69.96%)
Showing 8 of 8

US Market Status

Market Open — Closes in 49m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access